Study guide

11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion

Philippine Medical Technologists Licensure Examination MTLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety

1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards

2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function

2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice

3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology

3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology

4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety

4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria

5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology

6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology

6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods

7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods

7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control

8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders

8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry

9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders

9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures

11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions

11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin

12 Chapter 12: Clinical Serology and Immunology

12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology

13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control

14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens

14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens

15 Chapter 15: Histopathologic Techniques and Cytotechnology

15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records

16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics

16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics

11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion

Key Takeaways Explain This Topic AI

Differential centrifugation separates whole blood into packed red cells and platelet-rich plasma via a light spin, followed by a heavy spin to separate platelet concentrates from platelet-poor plasma.

PRBCs are stored at 1–6°C for 21 days (CPD), 35 days (CPDA-1), or 42 days (additive solutions AS-1/AS-3/AS-5); entering an aseptic system restricts shelf life to 24 hours at 1–6°C or 4 hours at room temperature.

Platelet concentrates require continuous gentle horizontal agitation at 20–24°C to sustain oxygen exchange and maintain pH > 6.2 >6.2 > 6.2 , with a strict 5-day expiration limit governed by bacterial contamination risk.

Fresh Frozen Plasma is frozen at ≤ − 18 ∘ C \le -18^\circ\text{C} ≤ − 1 8 ∘ C within 8 hours of phlebotomy and stored for 1 year; Cryoprecipitate derived from cold-thawed FFP contains ≥ 80 IU \ge 80\text{ IU} ≥ 80 IU Factor VIII and ≥ 150 mg \ge 150\text{ mg} ≥ 150 mg fibrinogen, and must NEVER be refrigerated once thawed.

Leukoreduction prevents febrile non-hemolytic reactions, CMV transmission, and HLA alloimmunization ( < 5.0 × 10 6 <5.0 \times 10^6 < 5.0 × 1 0 6 WBCs/unit); gamma irradiation (25 Gy) inactivates donor T-lymphocytes to prevent fatal TA-GVHD, reducing PRBC shelf life to 28 days.

Last updated: October 2026

Blood Component Preparation, Storage, Expiration, and Indications for Transfusion

Modern transfusion medicine is founded on the paradigm of component therapy —fractionating a single unit of whole blood into its constituent cellular and plasma derivatives. Transfusing specific components provides targeted therapeutic efficacy, avoids unnecessary circulatory volume overload, and allows one voluntary donor to save multiple patient lives. For medical technologists, rigorous adherence to differential centrifugation parameters, storage temperatures, expiration protocols, and specialized cellular modifications directly ensures product potency and patient survival.

1. Blood Component Preparation by Differential Centrifugation

Fractionation of whole blood into red blood cells, platelets, and plasma derivatives relies on the physical principle of differential centrifugation —exploiting distinct cellular densities ( R B C s > W B C s > P l a t e l e t s > P l a s m a RBCs > WBCs > Platelets > Plasma RBC s > W BC s > Pl a t e l e t s > Pl a s ma ) under calibrated centrifugal fields: ┌──────────────────────────────────────────────┐

  • │ Freshly Collected Whole Blood │
  • │ (Within 8 Hours) │
  • └──────────────────────┬───────────────────────┘
  • │
  • │ Light Spin Centrifugation
  • │ (Low speed, short duration)
  • ▼
  • ┌──────────────────────────────────────────────┐
  • │ Primary Separation Layer │
  • ├──────────────────────┬───────────────────────┤
  • │ Bottom Layer: │ Supernatant Layer: │
  • │ Packed Red Cells │ Platelet-Rich │
  • │ (PRBCs) │ Plasma (PRP) │
  • └──────────┬───────────┴───────────┬───────────┘
  • │ │
  • Add Additive Solution │ │ Heavy Spin Centrifugation
  • (AS-1, AS-3, AS-5) │ │ (High speed, long duration)
  • Store at 1-6°C (42 Days) │ ▼
  • │ ┌───────────────────────┐
  • │ │ Supernatant: │
  • │ │ Platelet-Poor Plasma │
  • │ │ (Freeze within 8 hrs) │
  • │ └───────────┬───────────┘
  • │ │ Freeze at ≤-18°C
  • │ ▼
  • │ ┌───────────────────────┐
  • │ │ Fresh Frozen Plasma │
  • │ │ (FFP, 1-year shelf) │
  • │ └───────────┬───────────┘
  • │ │ Thaw at 1-6°C
  • │ │ Cold precipitate
  • │ ▼
  • │ ┌───────────────────────┐
  • │ │ Cryoprecipitate (AHF) │
  • │ │ Refreeze at ≤-18°C │
  • │ └───────────────────────┘
  • │
  • ▼
  • ┌──────────────────────────────────────────────┐
  • │ Pellet: Platelet Concentrate │
  • │ Resuspend in 40-70 mL plasma │
  • │ Store at 20-24°C with agitation (5 Days) │
  • └──────────────────────────────────────────────┘
  • Centrifugation Phases

The Light Spin :

Parameters : Low centrifugal acceleration and short duration (e.g., ≈ 2 , 000 × g \approx 2,000 \times g ≈ 2 , 000 × g for 3 to 4 minutes 3\text{ to }4\text{ minutes} 3 to 4 minutes at 20 – 24 ∘ C 20\text{--}24^\circ\text{C} 20 – 2 4 ∘ C ).

Result : Dense red blood cells settle into a packed lower fraction, while platelets remain suspended in the supernatant plasma, yielding Platelet-Rich Plasma (PRP) .

The PRP is expressed into an attached satellite transfer pack using a manual or automated plasma extractor, leaving the packed red blood cells behind.

The Heavy Spin (Hard Spin) :

Parameters : High centrifugal acceleration and extended duration (e.g., ≈ 5 , 000 × g \approx 5,000 \times g ≈ 5 , 000 × g for 5 to 7 minutes 5\text{ to }7\text{ minutes} 5 to 7 minutes at 20 – 24 ∘ C 20\text{--}24^\circ\text{C} 20 – 2 4 ∘ C ).

Result : When applied to the PRP, platelets pellet densely at the bottom of the satellite pack. The clear supernatant, termed Platelet-Poor Plasma (PPP) , is expressed into a third satellite bag.

Platelet Rest Period : The tightly pelleted platelets must sit undisturbed at room temperature for 60 to 90 minutes 60\text{ to }90\text{ minutes} 60 to 90 minutes to allow disaggregation before gentle resuspension in 40 to 70 mL 40\text{ to }70\text{ mL} 40 to 70 mL of residual plasma.

A heavy spin applied directly to freshly collected whole blood can also be utilized when platelets are not being harvested, rapidly separating Packed Red Blood Cells from cell-free plasma.

Closed System vs. Open System Expiration Limits

Closed System : When components are prepared using integrated satellite packs interconnected by sterile factory tubing, the hermetic integrity of the system is maintained. Components retain their full regulatory shelf lives.

Open System Breach : If an aseptic seal is broken—such as spiking a port, pooling units without an approved sterile connecting device (SCD), or performing manual saline washing—the component is subject to strict shortened expiration limits due to potential airborne bacterial inoculation:

Storage at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C : Expiration is strictly 24 hours 24\text{ hours} 24 hours from the moment of breach.

Storage at Room Temperature ( 20 to 24 ∘ C 20\text{ to }24^\circ\text{C} 20 to 2 4 ∘ C ) : Expiration is strictly 4 hours 4\text{ hours} 4 hours from the moment of breach.

2. Packed Red Blood Cells (PRBCs)

Packed Red Blood Cells are indicated to increase oxygen-carrying capacity in patients with symptomatic anemia, acute surgical or traumatic hemorrhage, or bone marrow failure.

Storage and Transport Temperatures :

Storage : Maintained strictly at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C in monitored blood bank refrigerators equipped with continuous temperature recorders and audible alarms.

Transport : Maintained at 1 to 10 ∘ C 1\text{ to }10^\circ\text{C} 1 to 1 0 ∘ C during inter-facility transit in validated insulated containers containing wet ice (which floats above components, never in direct freezing contact).

Shelf Life by Preservative Formulation :

CPD / CP2D : 21 days.

CPDA-1 : 35 days.

Additive Solutions (AS-1, AS-3, AS-5) : 42 days.

Hematocrit and Quality Control Standards :

CPDA-1 units must maintain a hematocrit of ≤ 80 % \le 80\% ≤ 80% (typically 70 % – 80 % 70\%\text{--}80\% 70% – 80% ); higher hematocrit impedes infusion flow rates and deprives cells of sufficient nutrient plasma.

Additive solution units maintain a lower hematocrit of 55 % to 65 % 55\%\text{ to }65\% 55% to 65% , providing superior viscosity and rapid infusion kinetics.

Expected Adult Clinical Increment :

In a standard 70 kg 70\text{ kg} 70 kg , non-bleeding adult recipient, transfusion of one unit of PRBCs raises the circulating hemoglobin concentration by approximately 1.0 g/dL 1.0\text{ g/dL} 1.0 g/dL ( 10 g/L 10\text{ g/L} 10 g/L ) and the hematocrit by approximately 3 % 3\% 3% ( 0.03 0.03 0.03 ), evaluated at 24 hours post-transfusion.

3. Platelet Concentrates: Whole Blood-Derived vs. Single-Donor Apheresis

Platelets are indicated for the treatment or prophylaxis of severe bleeding in thrombocytopenia (due to chemotherapy, aplastic anemia, or marrow infiltration) and qualitative platelet functional defects. ┌──────────────────────────────────────────────┬──────────────────────────────────────────────┐

  • │ Whole Blood-Derived Platelet Concentrate │ Single-Donor Apheresis Platelet Unit │
  • ├──────────────────────────────────────────────┼──────────────────────────────────────────────┤
  • │ • Harvested from 1 unit whole blood │ • Collected via automated apheresis machine │
  • │ • Minimum Yield: ≥5.5 x 10^10 platelets │ • Minimum Yield: ≥3.0 x 10^11 platelets │
  • │ • Suspension Volume: 40-70 mL plasma │ • Suspension Volume: 200-300 mL plasma │
  • │ • Standard dose requires pooling 4-6 units │ • Equal to 6 pooled random donor units │
  • │ • Exposes recipient to multiple donors │ • Minimizes donor exposure, reduces HLA risk │
  • │ • Pooled open system expires in 4 hours │ • Closed system expires in 5 days │
  • └──────────────────────────────────────────────┴──────────────────────────────────────────────┘

Storage Temperature and Agitation Protocols :

Stored strictly at 20 to 24 ∘ C 20\text{ to }24^\circ\text{C} 20 to 2 4 ∘ C (room temperature) with continuous gentle horizontal agitation on dedicated flatbed agitators or rotating drums.

Pathophysiological Basis for Agitation : Constant motion prevents platelet clumping and facilitates continuous gas exchange across the plastic container membrane. Influx of oxygen ( O 2 O_2 O 2 ​ ) and efflux of carbon dioxide ( C O 2 CO_2 C O 2 ​ ) prevents anaerobic accumulation of lactic acid, maintaining product pH ≥ 6.2 \text{pH} \ge 6.2 pH ≥ 6.2 across the storage interval.

The Bacterial Proliferation Dilemma : Because platelets must be stored at ambient room temperature ( 20 – 24 ∘ C 20\text{--}24^\circ\text{C} 20 – 2 4 ∘ C ), they carry an exceptionally high risk of supporting rapid bacterial proliferation from skin flora or transient donor bacteremia. Consequently, shelf life is strictly capped at 5 days 5\text{ days} 5 days (or 7 days with approved bacterial screening devices).

Clinical Increment :

One single-donor apheresis unit (or an equivalent pool of 4 to 6 whole blood-derived units) raises the adult platelet count by 30 , 000 to 50 , 000 / μ L 30,000\text{ to }50,000/\mu\text{L} 30 , 000 to 50 , 000/ μ L ( 30 to 50 × 10 9 / L 30\text{ to }50 \times 10^9/\text{L} 30 to 50 × 1 0 9 / L ) measured 1 hour post-transfusion in a non-bleeding, non-refractory recipient.

  • 4. Plasma Derivatives: Fresh Frozen Plasma, Thawed Plasma, and Cryoprecipitate
  • Fresh Frozen Plasma (FFP)

Preparation and Freezing : Plasma separated from whole blood and frozen to ≤ − 18 ∘ C \le -18^\circ\text{C} ≤ − 1 8 ∘ C within 8 hours of phlebotomy (or ≤ − 20 ∘ C \le -20^\circ\text{C} ≤ − 2 0 ∘ C in European standards).

Shelf Life :

1 year when stored at ≤ − 18 ∘ C \le -18^\circ\text{C} ≤ − 1 8 ∘ C .

7 years when stored at ultra-low temperatures of ≤ − 65 ∘ C \le -65^\circ\text{C} ≤ − 6 5 ∘ C .

Coagulation Factor Content : Contains normal plasma concentrations of all soluble clotting factors, including normal physiological levels of the heat-labile coagulation factors— Factor V and Factor VIII .

Thawing Protocol : Thawed at 30 to 37 ∘ C 30\text{ to }37^\circ\text{C} 30 to 3 7 ∘ C in a temperature-controlled, circulating water bath using a protective waterproof plastic overwrap (to prevent port contamination) or an approved dry microwave heating system. Once thawed, FFP is stored at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C and expires in 24 hours 24\text{ hours} 24 hours .

Thawed Plasma (Extended Storage) :

If thawed FFP is not infused within 24 hours, it may be relabeled as Thawed Plasma and retained at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C for up to 4 additional days (total 5 days from initial thaw).

Factor Activity Profile : Labile Factors V and VIII decline significantly (Factor VIII drops by 50 % 50\% 50% within 48 hours), but stable factors (Factor II, VII, IX, X, and fibrinogen) remain therapeutically robust. Thawed plasma is indicated for urgent warfarin reversal, massive transfusion resuscitation, and plasma exchange in Thrombotic Thrombocytopenic Purpura (TTP).

Cryoprecipitated Antihemophilic Factor (Cryoprecipitate / AHF)

Preparation Mechanics : FFP stored at ≤ − 18 ∘ C \le -18^\circ\text{C} ≤ − 1 8 ∘ C is allowed to thaw slowly at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C overnight. As the plasma liquefies, a cold-insoluble white precipitate remains. The unit is subjected to a heavy spin at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C , the supernatant cryo-depleted plasma is expressed leaving the precipitate in 10 to 15 mL 10\text{ to }15\text{ mL} 10 to 15 mL of plasma, and the container is refrozen at ≤ − 18 ∘ C \le -18^\circ\text{C} ≤ − 1 8 ∘ C within 1 hour .

Shelf Life : 1 year stored at ≤ − 18 ∘ C \le -18^\circ\text{C} ≤ − 1 8 ∘ C .

Mandatory Component Yield Standards :

Factor VIII:C : ≥ 80 International Units (IU) \ge 80\text{ International Units (IU)} ≥ 80 International Units (IU) per unit.

Fibrinogen : ≥ 150 mg \ge 150\text{ mg} ≥ 150 mg of clottable fibrinogen per unit (typically 200 – 250 mg 200\text{--}250\text{ mg} 200 – 250 mg ).

Also rich in von Willebrand factor (vWF) ( 40 % – 70 % 40\%\text{--}70\% 40% – 70% of original plasma), Factor XIII ( 20 % – 30 % 20\%\text{--}30\% 20% – 30% ), and Fibronectin .

Thawing, Storage, and Infusion Handling :

Thawed at 30 to 37 ∘ C 30\text{ to }37^\circ\text{C} 30 to 3 7 ∘ C in a water bath.

CRITICAL STORAGE RULE : Once thawed, Cryoprecipitate must be kept at 20 to 24 ∘ C 20\text{ to }24^\circ\text{C} 20 to 2 4 ∘ C (ROOM TEMPERATURE) ! It must NEVER be refrigerated at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C , because hypothermic temperatures cause fibrinogen and von Willebrand factor polymers to spontaneously reprecipitate, rendering the component unusable.

Expiration Post-Thaw : Single unpooled units expire in 6 hours 6\text{ hours} 6 hours at 20 – 24 ∘ C 20\text{--}24^\circ\text{C} 20 – 2 4 ∘ C . If pooled in an open system, the pooled component expires in 4 hours 4\text{ hours} 4 hours .

Clinical Indications : Hypofibrinogenemia ( < 100 mg/dL <100\text{ mg/dL} < 100 mg/dL ), acute Disseminated Intravascular Coagulation (DIC) with fibrinogen consumption, obstetrical hemorrhage (placental abruption, amniotic fluid embolism), dysfibrinogenemia, and Factor XIII deficiency.

5. Specialized Component Modifications ┌────────────────────────────────────────────────────────────────────────────────────────┐

  • │ Specialized Cellular Component Modifications │
  • ├─────────────────────────┬────────────────────────────┬─────────────────────────────────┤
  • │ Leukoreduction │ Gamma Irradiation │ Saline Washing │
  • ├─────────────────────────┼────────────────────────────┼─────────────────────────────────┤
  • │ • Goal: <5 x 10^6 WBCs │ • Dose: 25 Gy center │ • Removes >99% plasma proteins │
  • │ • Prevents FNHTR │ • Inactivates T-cells │ • Indicated for anti-IgA / │
  • │ • Prevents CMV spread │ • Prevents fatal TA-GVHD │ severe recurrent anaphylaxis │
  • │ • Halts HLA-alloimmune │ • Mandatory: blood kin, │ • Expires in 24 hrs at 1-6°C │
  • │ refractoriness │ immunocompromised │ • Eliminates extracellular K+ │
  • │ • Retains shelf life │ • Limits PRBCs to 28 days │ and microaggregates │
  • └─────────────────────────┴────────────────────────────┴─────────────────────────────────┘
  • Leukoreduction

Mechanism : High-efficiency mechanical depth filtration using polyester or polyurethane micro-fibers, applied pre-storage within 48 hours of phlebotomy.

Regulatory Standard : Final component must contain < 5.0 × 10 6 <5.0 \times 10^6 < 5.0 × 1 0 6 residual white blood cells per unit while retaining ≥ 85 % \ge 85\% ≥ 85% of original red blood cells.

Clinical Indications and Benefits :

Prevents Febrile Non-Hemolytic Transfusion Reactions (FNHTR) caused by recipient antileukocyte antibodies or cytokines (IL-1, IL-6, TNF- α \alpha α ) released by aging granulocytes.

Prevents transfusion transmission of Cytomegalovirus (CMV) and Human T-Cell Lymphotropic Virus (HTLV-I/II), because these viruses reside intracellularly within donor leukocytes ("CMV-safe blood").

Decreases recipient HLA class I alloimmunization , reducing the incidence of immune-mediated platelet refractoriness in multi-transfused oncology patients.

Gamma Irradiation

Mechanism : Exposure of cellular products (PRBCs, Platelets, Granulocytes) to a gamma radiation source (Cesium-137 or Cobalt-60) or specialized X-ray irradiators. The central dose delivered to the container must be at least 25 Gy 25\text{ Gy} 25 Gy ( 2 , 500 cGy 2,500\text{ cGy} 2 , 500 cGy ) , with no part of the bag receiving less than 15 Gy 15\text{ Gy} 15 Gy .

Biological Target : Crosslinks DNA in viable donor T-lymphocytes , completely abolishing their proliferative and mitotic capabilities without damaging non-nucleated red cells or platelets.

Absolute Prevention of TA-GVHD : Transfusion-Associated Graft-versus-Host Disease (TA-GVHD) occurs when donor T-lymphocytes engraft in a recipient whose immune system cannot reject them. The engrafted donor T-cells mount a lethal immune assault against host tissues (bone marrow, GI tract, liver, skin), leading to profound pancytopenia with a mortality rate exceeding 90 % 90\% 90% .

Mandatory Indications for Irradiation :

Directed donations from biological first-degree relatives (parents, siblings, children): Even in immunocompetent recipients, shared HLA haplotypes prevent the recipient's immune cells from recognizing the donor cells as foreign, enabling fatal donor lymphocyte engraftment.

HLA-matched or crossmatched platelet transfusions .

Severe immunocompromised recipients : Congenital cellular immunodeficiencies (SCID, DiGeorge syndrome), allogeneic or autologous hematopoietic stem cell transplant recipients, hematologic malignancies undergoing intensive therapy with purine analogs (fludarabine, cladribine).

Intrauterine transfusions and exchange transfusions in premature neonates .

Shelf Life Restriction : Gamma irradiation damages red cell membranes, accelerating potassium efflux during storage. Consequently, the shelf life of irradiated PRBCs is restricted to 28 days 28\text{ days} 28 days from the date of irradiation, or the original expiration date, whichever is shorter .

Saline Washing

Mechanism : Cellular components (PRBCs or platelets) are washed with 1 to 2 liters 1\text{ to }2\text{ liters} 1 to 2 liters of sterile normal saline ( 0.9 % NaCl 0.9\%\text{ NaCl} 0.9% NaCl ) using automated centrifugation cell washers, removing > 99 % >99\% > 99% of extracellular plasma proteins, microaggregates, and extracellular potassium.

Clinical Indications :

IgA-deficient patients with confirmed anti-IgA antibodies : Even minute traces ( < 10 μ g <10\ \mu\text{g} < 10 μ g ) of donor plasma IgA trigger catastrophic IgE/IgG-mediated anaphylactic shock.

Patients with severe, recurrent, life-threatening allergic or anaphylactic reactions unresponsive to pre-medication.

Neonatal hyperkalemic risk during rapid prime-volume cardiac bypass surgery.

Expiration Constraint : Because saline washing involves entering the unit via an open washing system, washed PRBCs must be stored at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C and expire strictly within 24 hours 24\text{ hours} 24 hours .

6. Comprehensive Blood Component Comparison Matrix

Blood Component Storage Temp Agitation Regulatory Shelf Life Key Contents / Minimum Yield Primary Clinical Indications

Packed Red Blood Cells (PRBCs) 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C None CPD: 21 days; CPDA-1: 35 days; AS-1/3/5: 42 days Volume 250 – 350 mL 250\text{--}350\text{ mL} 250 – 350 mL ; H c t ≤ 80 % Hct \le 80\% Hc t ≤ 80% (CPDA) or 55 – 65 % 55\text{--}65\% 55 – 65% (AS) Symptomatic anemia, surgical hemorrhage, acute blood loss. Elevates Hb by 1 g/dL 1\text{ g/dL} 1 g/dL / unit.

Platelets (Whole Blood-Derived) 20 to 24 ∘ C 20\text{ to }24^\circ\text{C} 20 to 2 4 ∘ C Continuous horizontal 5 days (unpooled closed); 4 hours (pooled open) ≥ 5.5 × 10 10 \ge 5.5 \times 10^{10} ≥ 5.5 × 1 0 10 platelets in 40 – 70 mL 40\text{--}70\text{ mL} 40 – 70 mL plasma; pH ≥ 6.2 \text{pH} \ge 6.2 pH ≥ 6.2 Bleeding from thrombocytopenia ( < 50 , 000 / μ L <50,000/\mu\text{L} < 50 , 000/ μ L ) or platelet dysfunction. Pool 4–6 units.

Platelets (Apheresis Single-Donor) 20 to 24 ∘ C 20\text{ to }24^\circ\text{C} 20 to 2 4 ∘ C Continuous horizontal 5 days ≥ 3.0 × 10 11 \ge 3.0 \times 10^{11} ≥ 3.0 × 1 0 11 platelets in 200 – 300 mL 200\text{--}300\text{ mL} 200 – 300 mL plasma; pH ≥ 6.2 \text{pH} \ge 6.2 pH ≥ 6.2 Severe thrombocytopenia, platelet refractoriness. Raises count by 30 , 000 – 50 , 000 / μ L 30,000\text{--}50,000/\mu\text{L} 30 , 000 – 50 , 000/ μ L .

Fresh Frozen Plasma (FFP) ≤ − 18 ∘ C \le -18^\circ\text{C} ≤ − 1 8 ∘ C (frozen); 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C (thawed) None Frozen: 1 year ( ≤ − 18 ∘ C \le -18^\circ\text{C} ≤ − 1 8 ∘ C ); Thawed: 24 hours ( 1 – 6 ∘ C 1\text{--}6^\circ\text{C} 1 – 6 ∘ C ) Volume 200 – 250 mL 200\text{--}250\text{ mL} 200 – 250 mL ; all clotting factors including labile Factors V and VIII Multiple coagulation factor deficiencies, DIC, massive transfusion, urgent warfarin reversal.

Thawed Plasma 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C None Up to 5 days from initial thaw Reduced FV and FVIII; stable factor levels maintained Trauma resuscitation, warfarin reversal, TTP plasma exchange.

Cryoprecipitate (AHF) ≤ − 18 ∘ C \le -18^\circ\text{C} ≤ − 1 8 ∘ C (frozen); 20 to 24 ∘ C 20\text{ to }24^\circ\text{C} 20 to 2 4 ∘ C (thawed) None Frozen: 1 year ; Thawed: 6 hours (single); Thawed pool: 4 hours ≥ 80 IU \ge 80\text{ IU} ≥ 80 IU Factor VIII:C; ≥ 150 mg \ge 150\text{ mg} ≥ 150 mg Fibrinogen; vWF, FXIII Hypofibrinogenemia ( < 100 mg/dL <100\text{ mg/dL} < 100 mg/dL ), DIC, dysfibrinogenemia, Factor XIII deficiency.

Leukoreduced PRBCs 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C None Same as baseline preservative (e.g., 42 days AS) < 5.0 × 10 6 <5.0 \times 10^6 < 5.0 × 1 0 6 residual WBCs; ≥ 85 % \ge 85\% ≥ 85% RBC recovery Prevention of FNHTR, CMV-safe transfusion, prevention of HLA immunization.

Irradiated PRBCs 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C None 28 days from irradiation or original expiry (shorter) Minimum 25 Gy central irradiation; non-viable T-cells Prevention of fatal TA-GVHD (blood relatives, immunodeficient, stem cell transplant).

Washed PRBCs 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C None 24 hours > 99 % >99\% > 99% plasma proteins removed; no extracellular K + K^+ K + Severe IgA deficiency with anti-IgA, recurrent life-threatening anaphylaxis.

  • 7. Storage Equipment, Transport, Inspection, and Issue
  • Storage and Transport Temperatures
  • Component Storage Transport
  • Whole blood and red cells 1 to 6 °C 1 to 10 °C

Platelets 20 to 24 °C with continuous gentle agitation 20 to 24 °C (as close to storage temperature as possible)

  • Frozen plasma and cryoprecipitate Frozen (commonly -18 °C or colder) Kept frozen, for example with dry ice
  • Thawed plasma 1 to 6 °C 1 to 10 °C
  • Thawed cryoprecipitate 20 to 24 °C 20 to 24 °C
  • Storage Equipment

Blood bank refrigerators, freezers, and platelet incubators are used only for blood, components, and reagents . They have continuous temperature monitoring and audible alarms set to sound before components go out of range.

Where recording is not automatic, temperatures are recorded at regular intervals (commonly every 4 hours), and alarm checks are documented. A power-failure plan states where components go if equipment fails.

Platelet agitators keep platelets suspended and allow gas exchange; a stopped agitator for an extended period harms platelet function.

Transport Containers

Validated insulated containers with wet ice (separated from direct contact with red cell bags) or refrigerant packs keep red cells at 1 to 10 °C. Each shipment carries a temperature indicator or a validated maximum transit time, and the receiving facility checks the temperature on arrival.

Visual Inspection Before Issue

Every unit is inspected before release. Do not issue a unit with:

Hemolysis (pink or red plasma or a red line at the red cell-plasma interface), or clots .

Abnormal color , such as purple or dark red cells or brown, green, or very cloudy plasma, which can signal bacterial contamination .

Leaks, broken seals , or illegible or mismatched labels.

Issue and Return

At issue, the technologist and the person receiving the unit check the recipient's identification and the unit number, ABO/Rh, expiration date, and compatibility record together, and both sign the issue record.

Units returned unused can be reissued only if the seals are intact and the facility's validated time and temperature limits were met. The traditional "30-minute rule" for red cells has largely been replaced by limits validated with temperature indicators or validated containers.